Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA

被引：38

作者：

Morrison, Vicki A. ^{[1
]}

Bell, Jill A. ^{[2
]}

Hamilton, Laurie ^{[3
]}

Ogbonnaya, Augustina ^{[3
]}

Shih, Huai-Che ^{[3
]}

Hennenfent, Kristin ^{[3
]}

Eaddy, Michael ^{[3
]}

Shou, Yaping ^{[2
]}

Galaznik, Aaron ^{[2
]}

机构：

[1] Univ Minnesota, Hennepin Cty Med Ctr, Hematol Oncol & Infect Dis, 701 Pk Ave Ste 310, Minneapolis, MN 55415 USA

[2] Millennium Pharmaceut Inc, 40 Landsdowne St, Cambridge, MA USA

[3] Xcenda LLC, 4114 Woodlands Pkwy,Suite 500, Palm Harbor, FL 34685 USA

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 25期

关键词：

cost; diffuse large B-cell lymphoma; economic burden; follicular lymphoma; healthcare utilization; real-world; retrospective; treatment; NON-HODGKIN-LYMPHOMA; UNITED-STATES; EPIDEMIOLOGY;

D O I：

10.2217/fon-2018-0267

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Evaluate healthcare costs and utilization of treated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients. Materials & methods: Adults with newly diagnosed DLBCL and FL between 1 January 2008 and 31 October 2015 were identified in the Optum claims database. Healthcare costs and utilization were assessed from diagnosis date until end of follow-up. Results: A total of 1267 DLBCL- and 1595 FL-treated patients were identified. Mean per-patient, per-month cost during follow-up was US$11,890 for DLBCL and US$10,460 for FL. Healthcare costs and utilization decreased from year 1 to 2 following diagnosis, due to a decrease in chemotherapy services, inpatient admissions and other outpatient services. Conclusion: The economic burden of treated DLBCL and FL is considerable, especially in the first year following diagnosis.

引用

页码：2627 / 2642

页数：16

共 14 条

[1]

[Anonymous], 2017, Cancer facts and figures

[2] B-Cell Non-Hodgkin Lymphoma: Targeting in on the Future [J].

Bello, Celeste ;

Sokol, Lubomir .

CANCER CONTROL, 2012, 19 (03) :171-172

[3] Economic impact of disease progression in follicular non-Hodgkin lymphoma [J].

Beveridge, Roy ;

Satram-Hoang, Sacha ;

Sail, Kavita ;

Darragh, Joseph ;

Chen, Clara ;

Forsyth, Michael ;

Reyes, Carolina .

LEUKEMIA & LYMPHOMA, 2011, 52 (11) :2117-2123

[4]

Byfield SD, 2014, J Cancer Ther, V5, P208, DOI [10.4236/jct.2014.52026, DOI 10.4236/JCT.2014.52026]

[5] New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy [J].

Chihara, Dai ;

Nastoupil, Loretta J. ;

Williams, Jessica N. ;

Lee, Paul ;

Koff, Jean L. ;

Flowers, Christopher R. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (05) :531-544

[6] Follicular lymphoma: 2015 update on diagnosis and management [J].

Freedman, Arnold .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (12) :1172-1178

[7]

Institute for Clinical and Economic Review, 2018, CHIM ANT TEC T CELL

[8] Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment [J].

Kutikova, Lucie ;

Bowman, Lee ;

Chang, Stella ;

Long, Stacey R. ;

Arning, Michael ;

Crown, William H. .

LEUKEMIA & LYMPHOMA, 2006, 47 (08) :1535-1544

[9] Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource [J].

Link, Brian K. ;

Maurer, Matthew J. ;

Nowakowski, Grzegorz S. ;

Ansell, Stephen M. ;

Macon, William R. ;

Syrbu, Sergei I. ;

Slager, Susan L. ;

Thompson, Carrie A. ;

Inwards, David J. ;

Johnston, Patrick B. ;

Colgan, Joseph P. ;

Witzig, Thomas E. ;

Habermann, Thomas M. ;

Cerhan, James R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3272-3278

[10] Projections of the Cost of Cancer Care in the United States: 2010-2020 [J].

Mariotto, Angela B. ;

Yabroff, K. Robin ;

Shao, Yongwu ;

Feuer, Eric J. ;

Brown, Martin L. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (02) :117-128

← 1 2 →